Target Name: WNK2
NCBI ID: G65268
Review Report on WNK2 Target / Biomarker Content of Review Report on WNK2 Target / Biomarker
WNK2
Other Name(s): WNK lysine deficient protein kinase 2 (WNK2) | protein kinase lysine-deficient 2 | SDCCAG43 | KIAA1760 | Protein kinase, lysine deficient 2 | protein kinase with no lysine 2 | mitogen-activated protein kinase kinase kinase | WNK lysine deficient protein kinase 2 | P/OKcl.13 | WNK2_HUMAN | Serine/threonine-protein kinase WNK2 | Protein kinase with no lysine 2 | NY-CO-43 | Antigen NY-CO-43 | antigen NY-CO-43 | serologically defined colon cancer antigen 43 | Protein kinase lysine-deficient 2 | Mitogen-activated protein kinase kinase kinase | Serologically defined colon cancer antigen 43 | PRKWNK2

Targeting WNK2: Potential Drug and Antibody Targets

WNK2 (WNK lysine deficient protein kinase 2) is a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and heart. It is a key regulator of cell proliferation and survival, and is involved in the development and progression of many diseases, including cancer.

In recent years, researchers have been increasingly interested in developing drugs that target WNK2 in order to treat various diseases. This is because WNK2 has been shown to play a role in a wide range of cellular processes that are important for human health, including the regulation of cell growth, differentiation, and survival.

One of the key challenges in developing drugs that target WNK2 is that the protein is highly expressed in many different tissues and organs, making it difficult to target with small molecules. However, researchers have been able to identify a number of potential drug targets for WNK2 that are located in specific tissues and organs.

One potential drug target for WNK2 is the protein called PDGF-BB (pluripotent derivative growth factor beta B). PDGF-BB is a protein that is produced by the cell in response to the presence of a specific signaling molecule called PDGF (pluripotent derivative growth factor). PDGF-BB has been shown to play a role in the regulation of cell survival and growth, and is often used in the treatment of various diseases, including cancer.

Research has suggested that PDGF-BB may be a potential drug target for WNK2 because the two proteins are highly co-expressed in many different tissues and organs. Additionally, studies have shown that inhibiting PDGF-BB activity can lead to a reduction in the activity of WNK2, suggesting that the two proteins may be involved in a coordinated signaling pathway.

Another potential drug target for WNK2 is the protein called NF-kappa-B (nuclear factor kappa B). NF-kappa-B is a protein that is involved in the regulation of various cellular processes, including inflammation and cell survival. It has been shown to play a role in the development and progression of many diseases, including cancer.

Research has suggested that NF-kappa-B may be a potential drug target for WNK2 because the two proteins are highly co-expressed in many different tissues and organs. Additionally, studies have shown that inhibiting NF-kappa-B activity can lead to a reduction in the activity of WNK2, suggesting that the two proteins may be involved in a coordinated signaling pathway.

In addition to these potential drug targets, researchers have also been interested in developing drugs that target WNK2 directly. This is because direct targeting of WNK2 with small molecules may be more effective than targeting it through its intermediate targets, such as PDGF-BB or NF-kappa-B.

One way to target WNK2 directly is through the use of small molecules that can inhibit the activity of WNK2 itself. These small molecules can be found in a variety of natural compounds, including herbs and spices that have been used for centuries for their medicinal properties.

For example, a team of researchers at the University of California, San Diego has developed a compound called WNK2 inhibitor-1, which is designed to inhibit the activity of WNK2. The team has shown that this compound is able to reduce the activity of WNK2 in a variety of cell types and tissues, including cancer cells and stem cells.

Another potential approach to targeting WNK2 directly is through the use of antibodies that are designed to selectively bind to WNK2. These antibodies can be used to either block the activity of WNK2 or to transport it to specific

Protein Name: WNK Lysine Deficient Protein Kinase 2

Functions: Serine/threonine kinase which plays an important role in the regulation of electrolyte homeostasis, cell signaling, survival, and proliferation. Acts as an activator and inhibitor of sodium-coupled chloride cotransporters and potassium-coupled chloride cotransporters respectively. Activates SLC12A2, SCNN1A, SCNN1B, SCNN1D and SGK1 and inhibits SLC12A5. Negatively regulates the EGF-induced activation of the ERK/MAPK-pathway and the downstream cell cycle progression. Affects MAPK3/MAPK1 activity by modulating the activity of MAP2K1 and this modulation depends on phosphorylation of MAP2K1 by PAK1. WNK2 acts by interfering with the activity of PAK1 by controlling the balance of the activity of upstream regulators of PAK1 activity, RHOA and RAC1, which display reciprocal activity

The "WNK2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about WNK2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

WNK3 | WNK4 | Wnt | WNT1 | WNT10A | WNT10B | WNT11 | WNT16 | WNT2 | WNT2B | WNT3 | WNT3A | WNT4 | WNT5A | WNT5B | WNT6 | WNT7A | WNT7B | WNT8A | WNT8B | WNT9A | WNT9B | WRAP53 | WRAP73 | WRN | WRNIP1 | WSB1 | WSB2 | WSCD1 | WSCD2 | WSPAR | WT1 | WT1-AS | WTAP | WTAPP1 | WTIP | WWC1 | WWC2 | WWC2-AS2 | WWC3 | WWOX | WWP1 | WWP2 | WWTR1 | WWTR1-AS1 | XAB2 | XACT | XAF1 | XAGE-4 | XAGE1A | XAGE1B | XAGE1D | XAGE2 | XAGE3 | XAGE5 | XBP1 | XCL1 | XCL2 | XCR1 | XDH | XG | XGY2 | XIAP | XIRP1 | XIRP2 | XIST | XK | XKR3 | XKR4 | XKR5 | XKR6 | XKR7 | XKR8 | XKR9 | XKRX | XKRY | XKRYP7 | XLOC_007697 | XLOC_008559 | XLOC_009911 | XNDC1N | XPA | XPC | XPC complex | XPNPEP1 | XPNPEP2 | XPNPEP3 | XPO1 | XPO4 | XPO5 | XPO6 | XPO7 | XPOT | XPR1 | XRCC1 | XRCC2 | XRCC3 | XRCC4 | XRCC5 | XRCC6